ReviewTrends in biotechnology2026
Can nanozymes make the leap to the clinic? Advances, hurdles, and prospects.
Review in Trends in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Catalytic lactate-regulatory nanosystems attenuate cellular senescence for atherosclerosis amelioration.Bioactive materials · 2026Article
- Electric Field-Empowered Nanozymes: From Passive Adaptation to Active Precision Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanozymes (enzyme-like catalytic nanomaterials) represent a new generation of artificial enzymes designed to overcome key limitations of their natural counterparts, including high production costs, low stability, and challenging storage requirements. Their versatility spans biosensing, bioimaging, therapeutics, and environmental remediation, attracting widespread interest across disciplines. Recent advances have moved nanozymes beyond benchtop proof of concept, with multiple in vivo studies and early clinical investigations demonstrating their translational potential. However, progress toward the clinic remains constrained by limited mechanistic understanding under physiologically relevant conditions; concerns over safety, biodegradability, and long-term efficacy; and uncertainties in scalable manufacturing, market feasibility, and regulatory approval. This review highlights recent breakthroughs in biomedical nanozymes and identifies key knowledge gaps that must be addressed to accelerate successful clinical translation and commercialization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.